65,437 trials
Partial Seizures
Primary: Treatment Emergent Non-Serious Adverse Events With Greater Than 5% Frequency — 6; 9; 4; 3 Participants
Cushing's Disease
Primary: Number of mUFC (Urinary Free Cortisol) Responders by Randomized Dose Group — 12; 21 Responders
Atrial Fibrillation · Esophagectomy
Primary: Incidence of Atrial Fibrillation — 6; 16 participants — p=0.02
Precancerous/Nonmalignant Condition · Prostate Cancer
Primary: Presence of Carcinoma of the Prostate as Measured by Biopsy — 48; 49 participants — p=0.73
Healthy Subjects
Primary: Cmax (Maximum Plasma Concentration) — 1782.286; 1840.111 ng/mL
Prostate Cancer
Primary: Confirmed Prostate-Specific Antigen (PSA) Response — 3.8 percentage of participants
Parkinson's Disease
Primary: Mean Change From Baseline in Total Daily OFF Time (Hours) to Week 20 (Including Last Observation Carried Forward [LOCF] Data) — -0.96; -0.93; -0.76 Hours
Acute Myeloid Leukemia · Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Primary: Remission Induction Response — 62; 4 participants
Epilepsy
Primary: Percentage Change in Total Partial Seizure Frequency Per 28 Days During Maintenance Phase Relative to the Baseline Phase — -23.25; -9.80 Percentage change
Lymphoma
Primary: 2-year Progression-free Survival — 59 percentage of participants
Smoking · Nicotine Dependence
Primary: Quit Attempt — 101; 132 participants
Smoking · Nicotine Dependence
Primary: Smoking Cessation — 6; 6 participants
Refractory Partial Seizures
Primary: Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) — -20.95; -26.34; -34.49 Percent…
Alzheimer's Disease
Primary: Change From Baseline to Week 24 in SIB Total Score — 2.6; 0.4 Scores on a scale
Lymphoma
Primary: 2-year Progression-free Survival in Patients Treated With Rituximab-CHOP-bortezomib Induction Therapy (RCHOP-V) Followed by Bortezomib Maintenance Therapy (VM) — 62…